Tokyo, July 17 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000062263) titled 'Passive Joint Movement in Patients with Functional Dyspepsia: A Single-Arm Pre-Post Pilot Study' on July 17.

Study Type: Interventional

Study Design: Basic Design - Single arm Randomization - Non-randomized Blinding - Open -no one is blinded Control - Uncontrolled

Primary Sponsor: Institute - Miyata Gastroenterology and Dermatology Clinic

Condition: Condition - Functional Dyspepsia Classification by malignancy - Others Genomic information - NO

Objective: Narrative objectives1 - The purpose of this study is to evaluate the efficacy and safety of Passive Joint Movement (PJM) in patients with functional dyspepsia and to investigate its effects on gastrointestinal symptoms, psychological symptoms, and autonomic nervous system-related parameters. Basic objectives2 - Safety,Efficacy

Intervention: Interventions/Control_1 - Passive Joint Movement (PJM) Participants receive standardized Passive Joint Movement (PJM), a manual therapy consisting of rhythmic passive movements applied to the major joints of the upper limbs, lower limbs, and trunk by a trained therapist according to a predefined protocol. Outcomes are evaluated before and after the intervention.

Eligibility: Age-lower limit - 20 years-old <= Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - Adults aged 20 years or older. Patients diagnosed with functional dyspepsia according to the Rome IV criteria. Patients in whom organic gastrointestinal diseases have been excluded by upper gastrointestinal endoscopy and other appropriate examinations. Patients who provided written informed consent. Key exclusion criteria - 1.Patients with organic gastrointestinal diseases (e.g., gastric cancer or peptic ulcer) identified by upper gastrointestinal endoscopy or other appropriate examinations. 2.Patients with a history of gastrointestinal surgery that may affect the evaluation of functional dyspepsia. 3.Patients with severe cardiovascular, respiratory, hepatic, or renal diseases. 4.Patients with severe psychiatric disorders or cognitive impairment that would interfere with study participation. 5.Pregnant or breastfeeding women. 6.Patients considered unsuitable for participation by the principal investigator. Target Size - 20

Recruitment Status: Recruitment status - Completed Date of protocol fixation - 2024 Year 09 Month 03 Day Date of IRB - 2024 Year 09 Month 09 Day Anticipated trial start date - 2025 Year 02 Month 25 Day Last follow-up date - 2026 Year 06 Month 30 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000071249

Disclaimer: Curated by HT Syndication.